Merck & Co., Inc. and Pfizer Inc., latest fiscal year, normalized from SEC EDGAR — every value links to the filing it came from.
| MRK | PFE | |
|---|---|---|
| Revenue | $65.01B FY2025 | $62.58B FY2025 |
| Net income | $18.25B FY2025 | $7.77B FY2025 |
| Net margin | 28.1% FY2025 | 12.4% FY2025 |
| Free cash flow | $12.36B FY2025 | $9.08B FY2025 |
| Total assets | $136.87B FY2025 | $208.16B FY2025 |
| Shareholders' equity | $52.61B FY2025 | $86.48B FY2025 |
| Diluted EPS | $7.28 FY2025 | $1.36 FY2025 |